Kisspeptin-10

Mechanism

The "master switch" for your reproductive hormone system. It triggers your brain to release GnRH, which then triggers LH and FSH — the hormones that drive testosterone and estrogen production. Being studied as a fertility treatment and as an alternative to traditional hormone stimulation. Also interesting for PCT (post-cycle therapy).

Effects

**Reproductive/Neuroendocrine System (Tier 1 — Robust Human Trial Data):** Kisspeptin-10 is the C-terminal decapeptide of the full-length kisspeptin-54 (metastin), acting on the KISS1R (GPR54) receptor on hypothalamic GnRH neurons. It is the most potent known physiological stimulator of the HPG axis. A single IV bolus of kisspeptin-10 (1mcg/kg) produces a robust LH pulse within 30 minutes, with effects lasting 1-3 hours. It stimulates GnRH release from the hypothalamus, which then drives pituitary LH and FSH secretion. Unlike direct GnRH administration, kisspeptin works one level upstream — at the "master switch" of reproductive function. **HPG Axis Stimulation (Tier 1):** In healthy men, kisspeptin-10 (0.3-1.0mcg/kg IV) increases LH by 2-5 fold and testosterone by 1.5-2 fold within 60-90 minutes. In women, response varies by cycle phase — strongest LH response in pre-ovulatory phase (can trigger ovulation). FSH response is present but less dramatic than LH. The kisspeptin system is sexually dimorphic and sensitive to sex steroid feedback — in hypogonadal states (low testosterone), kisspeptin neurons are disinhibited, creating a more robust response to exogenous kisspeptin. **Fertility Effects (Tier 1-2):** Kisspeptin-54 (the longer form) has been used as an oocyte maturation trigger in IVF with promising results — Dr. Waljit Dhillo's group at Imperial College London showed comparable mature oocyte yield to HCG trigger with ZERO cases of OHSS (vs. ~7% with HCG). Kisspeptin-10 (shorter form) produces a more rapid but shorter-duration LH surge. Both forms are being investigated for IVF triggering, with kisspeptin-54 further ahead in clinical development. **Neurological/Behavioral (Tier 2):** Kisspeptin receptors are present in the amygdala and limbic system. fMRI studies show that kisspeptin administration enhances brain processing of sexual and romantic stimuli — increased activation in the posterior cingulate cortex and thalamus. Possible role in psychosexual function beyond hormonal effects. Men receiving kisspeptin-54 reported enhanced sexual desire in clinical research settings. **Metabolic Effects (Tier 3 — Emerging):** KISS1R is expressed in pancreatic beta cells. Kisspeptin may modulate insulin secretion — some evidence of improved glucose-stimulated insulin secretion. Potential link between reproductive status and metabolic function via kisspeptin signaling. Obesity attenuates kisspeptin sensitivity (negative feedback loop with metabolic status).

Practitioner Guide

**Emerging PCT Alternative — What Practitioners Are Using:** - Kisspeptin-10 is gaining traction in the TRT/hormone optimization community as a "physiological PCT" agent - Rationale: stimulates the ENTIRE HPG axis from the top down — hypothalamic GnRH → pituitary LH/FSH → testicular testosterone - Unlike Clomid (which blocks estrogen feedback at pituitary) or Nolvadex (which blocks estrogen at hypothalamus), kisspeptin directly activates the GnRH neurons - Unlike HCG (which only stimulates Leydig cells), kisspeptin restores the full neuroendocrine cascade **Practitioner PCT Protocol with Kisspeptin-10:** - Dose: 100-400mcg SC, 1-2x daily for 4-8 weeks post-cycle - Often combined with gonadorelin: kisspeptin 200mcg + gonadorelin 100mcg, both SC, 2x/week - Some practitioners start with kisspeptin + Clomid (25mg/day) for 4 weeks, then kisspeptin alone for 4 weeks - Lab monitoring: LH, FSH, total T, free T, estradiol at baseline, 2 weeks, and 4 weeks **What Reproductive Endocrinologists Are Observing:** - Dr. Waljit Dhillo (Imperial College London) — pioneer of kisspeptin in IVF: kisspeptin-54 as IVF trigger produces more "physiological" LH surge than HCG, dramatically reducing OHSS risk - IVF trigger protocol: kisspeptin-54, 1.6nmol/kg SC as single dose 36 hours before egg retrieval (in clinical trial settings) - Kisspeptin-10 (shorter form): faster onset, shorter duration — some researchers prefer it for diagnostic testing of HPG axis integrity - Key observation: kisspeptin response is BLUNTED in patients with long-term hypothalamic suppression (e.g., after years of TRT or long steroid cycles) — the system needs GnRH "priming" first - Implication for PCT: kisspeptin may work best in combination with low-dose gonadorelin (to re-sensitize pituitary) rather than as monotherapy **Kisspeptin as TRT Adjunct (Alongside Testosterone):** - Dose: 100-200mcg SC, 2-3x per week - Goal: maintain upstream HPG axis activity while on exogenous testosterone - Early practitioner reports suggest better fertility preservation than gonadorelin alone - Theoretical advantage: maintains hypothalamic GnRH neuron health and sensitivity - Practical disadvantage: more expensive than gonadorelin, less clinical data for this specific use **Important Clinical Caveats:** - Continuous/high-frequency kisspeptin exposure can DESENSITIZE KISS1R — leading to paradoxical HPG suppression (same principle as continuous GnRH causing suppression) - Pulsatile dosing is critical — daily or EOD dosing, NOT continuous infusion - Kisspeptin response is highly variable between individuals — some men show robust LH response, others minimal - Obese patients typically show blunted kisspeptin response (adiposity reduces KISS1R sensitivity) - Women: kisspeptin response varies dramatically with menstrual cycle phase — pre-ovulatory phase shows strongest response **Storage and Handling:** - Reconstitute with bacteriostatic water - Store reconstituted peptide refrigerated; use within 21-30 days - Peptide is relatively stable but avoid repeated freeze-thaw cycles

Dosing Protocols

Contraindications & Cautions

• hard stop — Hormone-sensitive cancers (breast, prostate, endometrial)
  Kisspeptin-10 potently stimulates the HPG axis, increasing GnRH, LH, FSH, and downstream sex hormones (estrogen, testosterone). Hormone-sensitive cancers are directly fueled by these hormones, and kisspeptin administration could accelerate tumor growth.
  Action: Do not use in patients with active or history of hormone-sensitive cancers. Obtain oncologist clearance.
• hard stop — Pregnancy
  Kisspeptin potently stimulates GnRH release and gonadotropin secretion. Disruption of the delicate hormonal balance during pregnancy could trigger uterine contractions, compromise the pregnancy, or cause hormonal disruption to the fetus.
  Action: Do not use during pregnancy. Absolutely contraindicated.
• hard stop — Breastfeeding
  No adequate safety data during lactation. HPG axis stimulation could affect hormone-dependent lactation.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  HPG axis-stimulating peptide. May disrupt pubertal development.
  Action: Do not provide to individuals under 18.
• requires physician — Polycystic ovary syndrome (PCOS)
  PCOS is characterized by dysregulated kisspeptin signaling and excessive LH pulsatility. Exogenous kisspeptin may further amplify LH hypersecretion and worsen the hyperandrogenic state.
  Action: Requires endocrinologist evaluation. Monitor LH, FSH, testosterone, and menstrual patterns.

Evidence

• Regulatory Involvement of Kisspeptin in Energy Balance and Reproduction

  Oyedokun PA, Akangbe MA, Akhigbe TM, Akhigbe RE (2025) — Cell Biochem Biophys — PMID: 39327386

  Kisspeptin (hypothalamic neuropeptide) modulates HPG axis through anorexigenic activity to maintain energy balance for optimal reproduction. Stimulates GnRH release, driving testosterone and germ cell production. Kisspeptin neurons also regulate satiety signaling — linking metabolic status to reproductive function. Potential therapeutic target for infertility, hypogonadism, and metabolic-reproductive disorders.

  moderate

• Kisspeptin-54 as a novel physiological approach to in vitro fertilisation treatment

  Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, Comninos AN, Peters D, Buckber K, Sherber V, Ghai K, Ghatei MA, Bloom SR, Dhillo WS (2015) — Journal of Clinical Endocrinology and Metabolism — PMID: 25412414

  Kisspeptin-54 subcutaneous injection effectively triggered oocyte maturation in IVF cycles as an alternative to hCG trigger. Patients achieved viable pregnancies with significantly lower risk of ovarian hyperstimulation syndrome (OHSS) — a major advantage over conventional hCG trigger. Mechanism involves physiological LH surge generation through endogenous GnRH release.

  moderate

• Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males

  Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, McGowan BM, Sherber V, Ghatei MA, Bloom SR (2005) — Journal of Clinical Endocrinology and Metabolism — PMID: 16030169

  Kisspeptin-54 (metastin) potently stimulated LH and FSH secretion in healthy men through activation of the hypothalamic GnRH pulse generator. IV bolus produced rapid and robust gonadotropin release. Established kisspeptin as the most potent known activator of the human reproductive axis and a key upstream regulator of GnRH neurons.

  moderate

Stacks featuring this peptide

Research Summary

**Tier 1 — Human Clinical Trials (multiple groups):** - Imperial College London (Dhillo lab): landmark studies showing kisspeptin-54 as safe, effective IVF trigger with zero OHSS cases (Lancet Diabetes Endocrinol 2014; multiple follow-up studies through 2024) - Kisspeptin-10 human studies: IV bolus (0.3-10mcg/kg) produces dose-dependent LH release in healthy men and women (Dhillo et al., J Clin Endocrinol Metab 2005-2017) - Phase II IVF trigger trial: kisspeptin-54 (1.6-12.8nmol/kg SC) vs. HCG trigger — comparable oocyte maturity rates (Abbara et al., 2015-2020) - fMRI studies: kisspeptin-54 enhances limbic brain responses to sexual stimuli in healthy men (Comninos et al., J Clin Invest 2017) - Safety: no serious adverse events reported in any human kisspeptin trial to date **Tier 2 — Established Physiology:** - KISS1/KISS1R is THE critical gatekeeper of puberty (loss-of-function mutations cause hypogonadotropic hypogonadism; gain-of-function causes precocious puberty) - Kisspeptin neurons integrate metabolic signals (leptin, insulin, ghrelin) with reproductive output — explains why underweight/overweight states impair fertility - NKB (neurokinin B) and dynorphin co-regulate kisspeptin neuron firing in the arcuate nucleus (KNDy neuron model) — pulsatile GnRH depends on this circuit - Kisspeptin neurons are the primary site of sex steroid negative feedback (estrogen and testosterone suppress kiss1 expression in arcuate nucleus) **Tier 3 — Emerging/Experimental:** - Oral kisspeptin analogs in development (poor oral bioavailability of native peptide) - Kisspeptin for hypoactive sexual desire disorder (HSDD) in women — early clinical exploration based on limbic activation data - Kisspeptin as PCT agent: practitioner-level case series (n=50-100 across multiple TRT clinics) showing faster testosterone recovery vs. traditional Clomid/Nolvadex PCT — NOT published in peer-reviewed literature yet - Investigation in functional hypothalamic amenorrhea (FHA): kisspeptin could restore HPG axis without exogenous hormones - Kisspeptin + GnRH agonist dual trigger for IVF: early-phase investigation - Kisspeptin in male infertility diagnosis: response to kisspeptin challenge may predict fertility recovery potential